Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Hca Midwest Health/research Medical Center
Kansas City, Missouri, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Tennessee Oncology
Chattanooga, Tennessee, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Sept 2016
- Primary completion
- 27 Jul 2021
- Completion
- 5 Oct 2021
- Last update posted
- 5 Dec 2023
- Registered enrollment
- 53
- Registry id
- NCT02843074
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.